Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 69,24 € (+28,32%). La mediana è 71,48 € (+32,47%).
| Acquista |
12 |
| Mantieni |
0 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
BrightSpring Health Services expects broad growth and strong cash flow profile
At the Jefferies conference BrightSpring Health Services presented a diversified growth model focused on specialty pharmacies, home health and hospice services. Management is targeting EBITDA growth of 15–20% over the next two years and expects operating cash flow of more than US$600 million for 2026 and roughly US$500 million of free cash flow (excluding the tax impact of the Community‑Living divestiture). Leverage could fall below 2.0x by year-end, creating room for acquisitions, share buybacks or dividends. Continued growth drivers include generic drug switches, exclusive medication partnerships, technology and AI deployments, and further consolidation opportunities in the home health market. » Altro su de.investing.com
BrightSpring accelerates growth in pharmacy and provider businesses
BrightSpring presented at the Wells Fargo Healthcare Conference a markedly accelerated EBITDA growth in the pharmacy segment (near 40% in 2025, >40% in H1 2026) and about 20% organic EBITDA growth in the provider business, supported by the integration of Amedisys LHC. Management highlighted investments in automation, AI and M&A as well as reduced leverage (near 2x EBITDA), which creates room for further acquisitions. The company expects 2026 to see the largest headwinds from IRA drug-price negotiations (around $15 million EBITDA impact), with a much smaller effect in 2027, and sees long-term tailwinds from LDD contracts, generic switches and expansion in the infusion and services business. » Altro su de.investing.com
Secondary placement weighs on BrightSpring Health Services
Shares of BrightSpring Health Services fell about 4.4% in after-hours trading after the announcement of a secondary placement of 15 million common shares by existing shareholders, including a subsidiary of Kohlberg Kravis Roberts and members of management. BrightSpring itself is not selling any shares and will not receive proceeds from the placement. At the same time, the company approved a share buyback of up to $60 million (up to 10% of the sold shares), to be executed concurrently with the placement; Goldman Sachs is acting as sole book-running manager. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 3,39 Mld | 27,08% |
| Utile lordo | 431,75 Mln | 35,76% |
| Utile netto | 75,95 Mln | 217,37% |
| EBITDA | 162,99 Mln | 112,52% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 10,42 Mld € |
Numero di azioni | 197,86 Mln |
Massimo/minimo a 52 settimane | 65,89 € - 27,38 € |
| Dividendi | No |
Beta | 1,88 |
Rapporto P/E | 41,21 |
Rapporto PEG | 0,12 |
Rapporto P/B | 5,93 |
Rapporto P/S | 0,81 |
Profilo aziendale
BrightSpring Health Services, Inc. gestisce una piattaforma di servizi sanitari domiciliari e di comunità negli Stati Uniti. La piattaforma della società si concentra sull'erogazione di servizi farmaceutici e di fornitura di prestazioni, inclusa l'assistenza clinica e di supporto in ambito domiciliare e comunitario, a favore di pazienti Medicare, Medicaid e di persone assicurate. Serve i pazienti tramite fornitori clinici e farmacisti. BrightSpring Health Services, Inc. era precedentemente nota come Phoenix Parent Holdings Inc. e ha cambiato denominazione in BrightSpring Health Services, Inc. nel maggio 2021. La società è stata fondata nel 1974 ed ha sede a Louisville, Kentucky.
| Nome | BrightSpring Health Services Inc |
| CEO | Jon Rousseau |
| Sede centrale | Louisville,
ky Stati Uniti |
| Sito web | |
| Industria | Fornitori e servizi sanitari |
| Quotazione in borsa | 26/01/2024 |
| Dipendenti | 23.500 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | BTSG |